Does pravastatin affect circulating levels of soluble TNF receptor 2 in hypercholesterolemic patients? [4]

Atherosclerosis

Volumn 166, Issue 2, 2003, Pages 413-414

  Ando, Hitoshi ^a   Takamura, Toshinari ^a   Kobayashi, Ken Ichi ^a   Misu, Hirofumi ^b   Osawa, Kenso ^b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b TONAMI GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; ENDOCRINOLOGY; FEMALE; GENERAL HOSPITAL; GLUCOSE INTOLERANCE; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOADSORBENT; LETTER; MALE; OUTPATIENT; PATIENT; PRIORITY JOURNAL;

ADULT; BLOOD CHEMICAL ANALYSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; DIET THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRAVASTATIN; PROBABILITY; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; SOLUBILITY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0037299674     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00378-7     Document Type: Letter

References (9)

1. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 103:2001;357-362.
2. Pahan K., Sheikh F.G., Namboodiri A.M.S., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100:1997;2671-2679.
3. Ando H., Takamura T., Ota T., Nagai Y., Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J. Pharmacol. Exp. Ther. 294:2000;1043-1046.
4. Solheim S., Seljeflot I., Arnesen H., Eritsland J., Eikvar L. Reduced levels of TNFα in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis. 157:2001;411-415.
5. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
6. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95:1995;2409-2415.
7. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:1992;323-329.
8. Fernandez-Real J.M., Broch M., Ricart W., Casamitjana R., Gutierrez C., Vendrell J., Richart C. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 47:1998;1757-1762.
9. Blann A.D., McCollum C.N. Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation. 22:1998;483-491.